Afatinib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Afatinib
Afatinib
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Afatinib, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| Known uses recorded for this drug | 1 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| non-small-cell lung carcinoma | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 11335N | Giotrif | Tablet 20 mg | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (irreversible ErbB family tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions. Thrombocytopenia has been reported as an adverse event in combination Phase 1 studies and EGFR-TKI safety analyses |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the PI. Full blood count, liver and renal function, and monitoring for diarrhoea and rash are reasonable |
| Handling Protection | Please refer to the PI and local cytotoxic or hazardous drug handling policies |
Safety Considerations
- Drug Interactions: 100 interactions were identified in the interaction screen. Most of those shown are Moderate, and one is Major.
- Major: aminolevulinic acid.
- Moderate (examples): clarithromycin, erythromycin, ketoconazole, cobicistat, dexamethasone, tacrolimus, abiraterone, alpelisib, quinine, ivacaftor, and aminolevulinic acid (topical).
- Minor: prucalopride.
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.